ATHENA-MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer

被引：0

作者：

Monk, Bradley J.

Parkinson, Christine

Lim, Myong Cheol

O'Malley, David M.

Oaknin, Ana

Wilson, Michelle K.

Coleman, Robert L.

Lorusso, Domenica

Oza, Amit M.

Ghamande, Sharad A.

Christopoulou, Athina

Prendergast, Emily

Demirkiran, Fuat

Littell, Ramey D.

Chudecka-Glaz, Anita M.

Morgan, Mark Aloysuis

Goble, Sandra M.

Hume, Stephanie

Fujiwara, Keiichi

Kristeleit, Rebecca

机构：

[1] Univ Arizona, Coll Med, Tucson, AZ 85721 USA

[2] Creighton Univ, Univ Sch Med, Phoenix, AZ USA

[3] Addenbrookes Hosp, Med Oncol, Cambridge, England

[4] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea

[5] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH 43210 USA

[6] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vail dHebron Barcelona Hosp Campus, Barcelona, Spain

[7] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand

[8] US Oncol Res, The Woodlands, TX USA

[9] Fdn Univ Policlin A Gemelli IRCCS, MITO, Rome, Italy

[10] Fdn Univ Policlin A Gemelli IRCCS, Gynecol Oncol Unit, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Rome, Italy

[12] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[13] Augusta Univ, Dept Obstet & Gynecol, Augusta, GA USA

[14] St Andrews Gen Hosp Patras, Med Oncol Unit, Patras, Greece

[15] Minnesota Oncol, Gynecol Oncol, Minneapolis, MN USA

[16] Istanbul Univ, Fac Med, Dept Gynecol Oncol, Istanbul, Turkey

[17] Kaiser Permanente Northern Calif, Gynecol Canc Program, San Francisco, CA USA

[18] Independent Publ Clin Hosp 2 PUM, Dept Surg Gynecol & Gynecol Oncol Adults & Girls, Szczecin, Poland

[19] Univ Penn Hlth Syst, Div Gynecol Oncol, Philadelphia, PA USA

[20] Clovis Oncol Inc, Biostat, Boulder, CO USA

[21] Clovis Oncol Inc, Clin Dev, Boulder, CO USA

[22] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan

[23] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA5500

引用

页数：1

共 50 条

[41] Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
Wu, Xiaohua
Sun, Yang
Yang, Hongying
Wang, Jing
Lou, Hanmei
Li, Dan
Wang, Ke
Zhang, Hui
Wu, Tao
Li, Yuzhi
Wang, Chunyan
Li, Guiling
Wang, Yifeng
Li, Dapeng
Tang, Ying
Pan, Mei
Cai, Hongyi
Wang, Weihu
Yang, Bing
Qian, Hua
Tian, Qiuhong
Yao, Desheng
Cheng, Ying
Wei, Bing
Li, Xiumin
Wang, Tao
Hao, Min
Wang, Xiaohong
Wang, Tiejun
Ran, Juntao
Zhu, Hong
Zhu, Lijing
Liu, Xianling
Li, Yunxia
Chen, Lihong
Li, Qingshan
Yan, Xiaojian
Wang, Fei
Cai, Hongbing
Zhang, Yunyan
Liang, Zhiqing
Liu, Funan
Huang, Yi
Xia, Bairong
Qu, Pengpeng
Zhu, Genhai
Chen, Youguo
Song, Kun
Sun, Meili
Chen, Zhengzheng
LANCET, 2024, 404 (10463): : 1668 - 1676
[42] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC)
Glisson, Bonnie
Kazarnowicz, Andrzej
Nackaerts, Kristiaan
Orlov, Sergey
Ramlau, Rodryg
Besse, Benjamin
Cobo Dols, Manuel
Menon, Hari
Paz-Ares Rodriguez, Luis
Zhang, Yilong
Zhu, Min
Jiang, Yizhou
Loh, Elwyn
Gansert, Jennifer
Dubey, Sarita
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S220 - S221
[43] VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Vergote, I. B.
Fidalgo, A. Pyrez
Hamilton, E.
Valabrega, G.
Van Gorp, T.
Sehouli, J.
Cibula, D.
Levy, T.
Welch, S.
Richardson, D. L.
Alia, E. M. Guerra
Scambia, G.
Henry, S.
Wimberger, P.
Miller, D.
Martinez, J.
Monk, B. J.
Shacham, S.
Mirza, M. R.
Makker, V.
ANNALS OF ONCOLOGY, 2022, 33 (04) : 448 - 450
[44] Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Monk, Bradley
Tewari, Krishnansu
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Nguyen, Allison Martin
Monberg, Matthew
Colombo, Nicoletta
Lorusso, Domenica
GYNECOLOGIC ONCOLOGY, 2022, 166 : S18 - S18
[45] Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Cheng, Ying
Fan, Yun
Zhao, Yanqiu
Huang, Dingzhi
Li, Xingya
Zhang, Peng
Kang, Mafei
Yang, Nong
Zhong, Diansheng
Wang, Zhen
Yu, Yan
Zhang, Yu
Zhao, Jun
Qin, Tai
Chen, Chenqi
Leaw, Shiangjiin
Zheng, Wenjuan
Song, Yong
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : 1073 - 1085
[46] Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Martin, A. Gonzalez
Perez, M. J. Rubio
Heitz, F.
Christensen, R. D.
Colombo, N.
Van Gorp, T.
Oaknin, A.
Leary, A.
Garcia, L. Gaba
Lebreton, C.
Gonzalez, L. M. De Sande
Marin, M. Romeo
Redondo, A.
Ginesta, M. P. Barretina
Fidalgo, J. A. Perez
Bertran, A. Santaballa
Bermejo-Perez, M. J.
Bruchim, I.
Ray-Coquard, I. L.
Selle, F.
ANNALS OF ONCOLOGY, 2023, 34 : S1278 - S1279
[47] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF GEFITINIB (G) VERSUS PLACEBO (P) IN PATIENTS (PTS) WITH ADVANCED NSCLC, NON-PROGRESSING AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (EORTC 08021-ILCP)
Surmont, V. F.
Gaafar, R. M.
Scagliotti, G. V.
van Klaveren, R. J.
Papamichael, D.
Hasan, B.
Torri, V.
van Meerbeeck, J. P.
ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124
[48] Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Powles, Thomas
Huddart, Robert A.
Elliott, Tony
Sarker, Shah-Jalal
Ackerman, Charlotte
Jones, Robert
Hussain, Syed
Crabb, Simon
Jagdev, Satinder
Chester, John
Hilman, Serena
Beresford, Mark
Macdonald, Graham
Santhanam, Sundar
Frew, John A.
Stockdale, Andrew
Hughes, Simon
Berney, Daniel
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 48 - +
[49] Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) trial.
Pfisterer, J.
Berek, J. S.
Casado, A.
Cwiertka, K.
Pinter, T.
Pluzanska, A.
Pujade-Lauraine, E.
Scambia, G.
Vermorken, J. B.
Simonelli, C.
Bertolotti, M.
Capriati, A.
Sabbatini, P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[50] Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy -: a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group
Hilpert, F
Stähle, A
Tomé, O
Burges, A
Rossner, D
Späthe, K
Heilmann, V
Richter, B
du Bois, A
SUPPORTIVE CARE IN CANCER, 2005, 13 (10) : 797 - 805

← 1 2 3 4 5 →